

Supplementary data

Investigation of the in vivo metabolism of sibirioside A and angoroside C in rats by HPLC-ESI-IT-TOF-MSⁿ

Yi-Fan Zhang, Li-Jia Liu, Feng Xu, Ming-Ying Shang*, Guang-Xue Liu,

Shao-Qing Cai

Division of Pharmacognosy, School of Pharmaceutical Sciences, Peking University Health Science Center, No.38, Xueyuan Road, Beijing 100191, China; zhangyf0911@163.com (Y.-F.Z.); lily199109231@163.com (L.-J.L.); xufeng_pharm@163.com (F.X.); guangxl@bjmu.edu.cn (G.-X.L.); sqcai@bjmu.edu.cn (S.-Q.C.)

* Correspondence: myshang@bjmu.edu.cn (M.-Y.S.); Tel.: +86-10-8280-2534

Figure S1. The ESI-IT-TOF MSⁿ spectra of angoroside C (A) and sibirioside A (B).




Figure S2. The negative ion mode EIC of SM1 in feces samples (A) blank group; (B) sibirioside A group.




Figure S3. The negative ion mode EIC of SM2 in feces samples (A) blank group; (B) sibirioside A group.




Figure S4. The negative ion mode EIC of SM3 in feces samples (A) blank group; (B) sibirioside A group.




Figure S5. The negative ion mode EIC of SM4 in stomach samples (A) blank group; (B) sibirioside A group.




Figure S6. The negative ion mode EIC of AM1 in urine samples (A) blank group; (B) angoroside C group.




Figure S7. The negative ion mode EIC of AM2 in urine samples (A) blank group; (B) angoroside C group.




Figure S8. The negative ion mode EIC of AM3 in urine samples (A) blank group; (B) angorosiide C group.




Figure S9. The negative ion mode EIC of AM4, AM5, AM6 in urine samples (A) blank group; (B) angorosiide C group.




Figure S10. The negative ion mode EIC of AM7 in urine samples (A) blank group; (B) angoroside C group.




Figure S11. The negative ion mode EIC of AM8, AM9 in urine samples (A) blank group; (B) angoroside C group.




Figure S12. The negative ion mode EIC of AM10, AM11 in urine samples (A) blank group; (B) angoraside C group.




Figure S13. The negative ion mode EIC of AM12, AM13, AM14 in urine samples (A) blank group; (B) angoraside C group.




Figure S14. The negative ion mode EIC of AM15 in urine samples (A) blank group; (B) angorosiide C group.




Figure S15. The negative ion mode EIC of AM16, AM17 in urine samples (A) blank group; (B) angorosiide C group.




Figure S16. The negative ion mode EIC of AM18 in urine samples (A) blank group; (B) angoroside C group.




Figure S17. The negative ion mode EIC of AM19 in urine samples (A) blank group; (B) angoroside C group.




Figure S18. The negative ion mode EIC of AM20, AM21 in urine samples (A) blank group; (B) angoroside C group.




Figure S19. The negative ion mode EIC of AM22, AM23 in urine samples (A) blank group; (B) angoroside C group.




Figure S20. The negative ion mode EIC of AM24 in feces samples (A) blank group; (B) angoroside C group.




Figure S21. The negative ion mode EIC of AM25 in feces samples (A) blank group; (B) angoroside C group.

Table S1. The predict results of bioactivities for metabolites of sibirioside A and angoroside C.

| No. | Potential Targets | Potential Activities | Target ID | Score |
|-----|-------------------------------|-----------------------------------|-----------|-------|
| SM1 | GTPase HRas | Anti-cancer | RASH | 4.299 |
| | Angiogenin | Anti myotrophic lateral sclerosis | ANGI | 3.904 |
| | Aldose reductase | Anti-diabetes | ALDR | 3.821 |
| | Glucose-6-phosphate isomerase | Nonspherocytic hemolytic anemia | G6PI | 3.786 |
| | Cathepsin K | Osteogenic activity | CATK | 3.744 |
| | Nucleoside diphosphate | Anti-cancer | NDKB | 3.730 |

| | | | | |
|------------|--|-----------------------------------|------|-------|
| | kinase B | | | |
| | Insulin receptor | Anti-diabetes | INSR | 3.666 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 3.583 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | PUR9 | 3.582 |
| SM2 | GTPase HRas | Anti-cancer | RASH | 5.549 |
| | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 4.580 |
| | Aldose reductase | Anti-diabetes | ALDR | 4.404 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 4.393 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | PUR9 | 4.212 |
| | Insulin receptor | Anti-diabetes | INSR | 4.194 |
| | Angiogenin | Anti myotrophic lateral sclerosis | ANGI | 3.981 |
| | Fibrinogen gamma chain | Cardiovascular protection | FIBG | 3.840 |
| | Glucose-6-phosphate isomerase | Nonspherocytic hemolytic anemia | G6PI | 3.837 |
| | Hepatocyte growth factor receptor | Anti-cancer | MET | 3.778 |
| | Cathepsin K | Osteogenic activity | CATK | 3.763 |
| SM3 | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 4.373 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | BTK | 4.288 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 4.144 |
| | Insulin receptor | Anti-diabetes | INSR | 4.139 |
| | Aldose reductase | Anti-diabetes | ALDR | 3.936 |
| | GTPase HRas | Anti-cancer | RASH | 3.903 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | PUR9 | 3.885 |
| | Glucose-6-phosphate isomerase | Nonspherocytic hemolytic anemia | G6PI | 3.861 |
| | Cathepsin K | Osteogenic activity | CATK | 3.835 |
| AM2 | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 4.308 |
| | GTPase HRas | Anti-cancer | RASH | 4.219 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 4.059 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | PUR9 | 4.152 |
| | Insulin receptor | Anti-diabetes | INSR | 4.127 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 3.752 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 3.692 |
| | Angiogenin | Anti-myotrophic lateral sclerosis | ANGI | 3.616 |

| | | | | |
|------------|--|-----------------------------------|-------|-------|
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | BTK | 3.613 |
| | Angiotensin-converting enzyme | Cerebral protection | ACE | 3.533 |
| AM4 | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 4.351 |
| | Insulin receptor | Anti-diabetes | INSR | 4.096 |
| | Angiogenin | Anti myotrophic lateral sclerosis | ANGI | 3.915 |
| | Dual specificity mitogen-activated protein kinase kinase 1 | Cardiovascular protection | MP2K1 | 3.853 |
| | Angiotensin-converting enzyme | Cerebral protection | ACE | 3.815 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 3.780 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 3.714 |
| | GTPase HRas | Anti-cancer | RASH | 3.714 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 3.704 |
| | Serum albumin | | ALBU | 3.518 |
| AM5 | Angiogenin | Anti-myotrophic lateral sclerosis | ANGI | 4.076 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 3.878 |
| | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 3.837 |
| | GTPase HRas | Anti-cancer | RASH | 3.743 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | PUR9 | 3.706 |
| | Prothrombin | Cerebrovascular protection | THRB | 3.683 |
| | Dual specificity mitogen-activated protein kinase kinase 1 | Cardiovascular protection | MP2K1 | 3.651 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 3.617 |
| | Tyrosine-protein kinase BTK | Anti chronic leukemia | BTK | 3.611 |
| | Insulin receptor | Anti-diabetes | INSR | 3.600 |
| AM6 | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 4.501 |
| | Insulin receptor | Anti-diabetes | INSR | 4.321 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 4.104 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 3.810 |
| | Angiotensin-converting enzyme | Cerebral protection | ACE | 3.763 |
| | Dual specificity mitogen-activated protein kinase kinase 1 | Cardiovascular protection | MP2K1 | 3.739 |

| | | | | | |
|-------------|---|-------------------------------|-----------|-------|-------|
| | Glucose-6-phosphate 1-dehydrogenase | Nonspherocytic anemia | hemolytic | G6PD | 3.649 |
| AM8 | Nucleoside diphosphate kinase B | Anti-cancer | | NDKB | 4.434 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | | BTK | 4.410 |
| | Angiogenin | Anti-myotrophic sclerosis | lateral | ANGI | 4.246 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | | KPYR | 4.229 |
| | GTPase HRas | Anti-cancer | | RASH | 4.077 |
| | Inositol monophosphatase 1 | Anti-manic anti-depressant | and | IMPA1 | 3.924 |
| | Carbonic anhydrase 2 | Osteogenic activity | | CAH2 | 3.861 |
| | Glucose-6-phosphate isomerase | Nonspherocytic anemia | hemolytic | G6PI | 3.844 |
| | Fibrinogen gamma chain | Cardiovascular protection | | FIBG | 3.833 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | | PUR9 | 3.704 |
| AM9 | Nucleoside diphosphate kinase B | Anti-cancer | | NDKB | 4.397 |
| | GTPase HRas | Anti-cancer | | RASH | 4.105 |
| | Angiogenin | Anti myotrophic sclerosis | lateral | ANGI | 4.095 |
| | Coagulation factor VII | Anti-coagulopathy | | FA7 | 4.077 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | | PUR9 | 4.046 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | | BTK | 3.994 |
| | Glucose-6-phosphate 1-dehydrogenase | Nonspherocytic anemia | hemolytic | G6PD | 3.905 |
| | Carbonic anhydrase 2 | Osteogenic activity | | CAH2 | 3.810 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | | KPYR | 3.797 |
| | Insulin receptor | Anti-diabetes | | INSR | 3.742 |
| | Fibrinogen gamma chain | Cardiovascular protection | | FIBG | 3.664 |
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | | MK10 | 3.653 |
| | Angiotensin-converting enzyme | Cerebral protection | | ACE | 3.629 |
| AM10 | Angiogenin | Anti-myotrophic sclerosis | lateral | ANGI | 4.628 |
| | GTPase HRas | Anti-cancer | | RASH | 4.482 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | | BTK | 4.445 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | | KPYR | 4.253 |

| | | | | |
|-------------|---|-----------------------------------|-------|-------|
| | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 4.083 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 3.995 |
| | Glucose-6-phosphate isomerase | Nonspherocytic hemolytic anemia | G6PI | 3.871 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 3.832 |
| | Insulin receptor | Anti-diabetes | INSR | 3.813 |
| AM11 | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 4.617 |
| | Angiogenin | Anti-myotrophic lateral sclerosis | ANGI | 4.398 |
| | GTPase HRas | Anti-cancer | RASH | 4.269 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 4.248 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | BTK | 4.050 |
| | Glucose-6-phosphate isomerase | Nonspherocytic hemolytic anemia | G6PI | 3.872 |
| | cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Anti-stroke | PDE4D | 3.848 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 3.842 |
| | Insulin receptor | Anti-diabetes | INSR | 3.773 |
| AM12 | GTPase HRas | Anti-cancer | RASH | 4.089 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 3.795 |
| | Glucose-6-phosphate 1-dehydrogenase | Nonspherocytic hemolytic anemia | G6PD | 3.782 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 3.775 |
| | Inositol monophosphatase 1 | Anti-manic and anti-depressant | IMPA1 | 3.742 |
| | Aldose reductase | Anti-diabetes | ALDR | 3.708 |
| | Ornithine aminotransferase | Anti-hyperornithinemia | OAT | 3.699 |
| | Tyrosine-protein kinase Lck | Anti-leukemias | LCK | 3.599 |
| | Dual specificity mitogen-activated protein kinase 1 | Cardiovascular protection | MP2K1 | 3.529 |
| | Glucose-6-phosphate isomerase | Nonspherocytic hemolytic anemia | G6PI | 3.496 |
| | Serine--pyruvate aminotransferase | Anti-hyperoxaluria | SPYA | 3.434 |
| | Insulin receptor | Anti-diabetes | INSR | 3.432 |
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | MK10 | 3.418 |
| | Angiogenin | Anti-myotrophic lateral | ANGI | 3.384 |

| | | | | |
|-------------|---|---------------------------------------|-------|-------|
| | | sclerosis | | |
| AM13 | GTPase HRas | Anti-cancer | RASH | 3.889 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 3.591 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 3.468 |
| | Glucose-6-phosphate 1-dehydrogenase | Nonspherocytic hemolytic anemia | G6PD | 3.408 |
| | Angiogenin | Anti-myotrophic lateral sclerosis | ANGI | 3.388 |
| | Insulin receptor | Anti-diabetes | INSR | 3.323 |
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | MK10 | 3.246 |
| | Inositol monophosphatase 1 | Anti-manic and anti-depressant | IMPA1 | 3.156 |
| | Aldose reductase | Anti-diabetes | ALDR | 2.992 |
| | Ornithine aminotransferase | Anti-hyperornithinemia | OAT | 2.970 |
| | Complement subcomponent C1s | Anti-autoimmune diseases | C1S | 2.910 |
| | cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Anti-stroke | PDE4D | 2.906 |
| | Catalase | Anti-acatalasia | CATA | 2.896 |
| | Serum albumin | Anti-dysalbuminemic hyperthyroxinemia | ALBU | 2.887 |
| | Prothrombin | Anti-dysprothrombinemia | THRB | 2.884 |
| AM14 | GTPase HRas | Anti-cancer | RASH | 3.770 |
| | Angiogenin | Anti-myotrophic lateral sclerosis | ANGI | 3.388 |
| | Ornithine aminotransferase | Anti-hyperornithinemia | OAT | 3.338 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 3.316 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | BTK | 3.313 |
| | Glucose-6-phosphate 1-dehydrogenase | Nonspherocytic hemolytic anemia | G6PD | 3.034 |
| | Aldose reductase | Anti-diabetes | ALDR | 2.992 |
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | MK10 | 2.955 |
| | Transthyretin | Anti-amyloidosis | TTHY | 2.952 |
| | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 2.946 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 2.923 |
| | Complement subcomponent C1s | Anti-autoimmune diseases | C1S | 2.910 |
| | Tyrosine-protein kinase | Anti-leukemias | LCK | 2.868 |

| | | | | | |
|-------------|---|-------------------------------|-----------|-------|-------|
| | Lck | | | | |
| AM15 | Insulin receptor | Anti-diabetes | | INSR | 5.223 |
| | Glucose-6-phosphate isomerase | Nonspherocytic anemia | hemolytic | G6PI | 4.924 |
| | GTPase HRas | Anti-cancer | | RASH | 4.901 |
| | Inositol monophosphatase 1 | Anti-manic anti-depressant | and | IMPA1 | 4.873 |
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | | MK10 | 4.676 |
| | Tyrosine-protein kinase Lck | Anti-leukemias | | LCK | 4.390 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | | KPYR | 4.333 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | | BTK | 4.156 |
| | Ornithine aminotransferase | Anti-hyperornithinemia | | OAT | 4.117 |
| | Angiogenin | Anti myotrophic sclerosis | lateral | ANGI | 4.106 |
| | Coagulation factor VII | Anti-coagulopathy | | FA7 | 4.082 |
| | cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Anti-stroke | | PDE4D | 4.106 |
| AM18 | Insulin receptor | Anti-diabetes | | INSR | 5.187 |
| | Inositol monophosphatase 1 | Anti-manic anti-depressant | and | IMPA1 | 4.910 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | | BTK | 4.874 |
| | GTPase HRas | Anti-cancer | | RASH | 4.859 |
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | | MK10 | 4.627 |
| | Coagulation factor VII | Anti-coagulopathy | | FA7 | 4.508 |
| | Glucose-6-phosphate isomerase | Nonspherocytic anemia | hemolytic | G6PI | 4.497 |
| | Angiotensin-converting enzyme | Cerebral protection | | ACE | 4.440 |
| | Ornithine aminotransferase | Anti-hyperornithinemia | | OAT | 4.246 |
| | Angiogenin | Anti-myotrophic sclerosis | lateral | ANGI | 4.233 |
| AM19 | Insulin receptor | Anti-diabetes | | INSR | 5.277 |
| | Inositol monophosphatase 1 | Anti-manic anti-depressant | and | IMPA1 | 4.960 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | | BTK | 4.865 |
| | GTPase HRas | Anti-cancer | | RASH | 4.965 |

| | | | | |
|-------------|---|-----------------------------------|-------|-------|
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | MK10 | 4.540 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 4.484 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 4.429 |
| | Angiogenin | Anti-myotrophic lateral sclerosis | ANGI | 4.258 |
| | Glucose-6-phosphate isomerase | Nonspherocytic hemolytic anemia | G6PI | 4.168 |
| | Aldose reductase | Anti-diabetes | ALDR | 4.023 |
| AM24 | Tyrosine-protein kinase BTK | Anti-chronic leukemia | BTK | 3.786 |
| | Insulin receptor | Anti-diabetes | INSR | 3.753 |
| | GTPase HRas | Anti-cancer | RASH | 3.499 |
| | Aldose reductase | Anti-diabetes | ALDR | 3.210 |
| | Mitogen-activated protein kinase 10 | Anti-epileptic encephalopathy | MK10 | 3.161 |
| | Carbonic anhydrase 2 | Osteogenic activity | CAH2 | 3.108 |
| | Prothrombin | Cerebrovascular protection | THRB | 3.071 |
| | Coagulation factor VII | Anti-coagulopathy | FA7 | 3.053 |
| | Glucose-6-phosphate 1-dehydrogenase | Nonspherocytic hemolytic anemia | G6PD | 2.988 |
| AM25 | GTPase HRas | Anti-cancer | RASH | 4.556 |
| | Bifunctional purine biosynthesis protein | Neuroprotective effect | PUR9 | 4.465 |
| | Insulin receptor | Anti-diabetes | INSR | 4.264 |
| | Tyrosine-protein kinase BTK | Anti-chronic leukemia | BTK | 4.247 |
| | Pyruvate kinase PKLR | Anti-hemolytic anemia | KPYR | 4.161 |
| | Nucleoside diphosphate kinase B | Anti-cancer | NDKB | 4.144 |
| | Angiotensin-converting enzyme | Cerebral protection | ACE | 3.892 |
| | Inosine-5'-monophosphate dehydrogenase 1 | retinitis pigmentosa | IMDH1 | 3.771 |
| | Glucose-6-phosphate 1-dehydrogenase | Nonspherocytic hemolytic anemia | G6PD | 3.749 |
| | Signal transducer and activator of transcription 1-alpha/beta | Immune related | STAT1 | 3.746 |